Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Alnylam Pharmaceuticals stock
Learn how to easily invest in Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,665 staff and has a trailing 12-month revenue of around $960.9 million.
How to buy Alnylam Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ALNY. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Alnylam Pharmaceuticals stock price (NASDAQ: ALNY)Use our graph to track the performance of ALNY stocks over time.
Alnylam Pharmaceuticals shares at a glance
|Latest market close||$224.91|
|52-week range||$117.58 - $242.97|
|50-day moving average||$227.22|
|200-day moving average||$187.48|
|Wall St. target price||$246.39|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-7.49|
Buy Alnylam Pharmaceuticals stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Alnylam Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alnylam Pharmaceuticals price performance over time
|1 week (2023-01-27)||-2.79%|
|1 month (2023-01-03)||-3.72%|
|3 months (2022-11-03)||4.26%|
|6 months (2022-08-03)||6.08%|
|1 year (2022-01-30)||N/A|
|2 years (2021-02-03)||48.70%|
|3 years (2020-02-03)||96.15%|
|5 years (2018-02-02)||80.65%|
Alnylam Pharmaceuticals financials
|Revenue TTM||$960.9 million|
|Gross profit TTM||$704.1 million|
|Return on assets TTM||-14.11%|
|Return on equity TTM||-343.51%|
|Market capitalisation||$27.7 billion|
TTM: trailing 12 months
Alnylam Pharmaceuticals share dividends
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.
Alnylam Pharmaceuticals share price volatility
Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $117.58 up to $242.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 0.5033. This would suggest that Alnylam Pharmaceuticals's shares are less volatile than average (for this exchange).
Alnylam Pharmaceuticals overview
Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals in the news
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
Frequently asked questionsWhat percentage of Alnylam Pharmaceuticals is owned by insiders or institutions?
Currently 0.523% of Alnylam Pharmaceuticals shares are held by insiders and 97.637% by institutions. How many people work for Alnylam Pharmaceuticals?
Latest data suggests 1,665 work at Alnylam Pharmaceuticals. When does the fiscal year end for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's fiscal year ends in December. Where is Alnylam Pharmaceuticals based?
Alnylam Pharmaceuticals's address is: 675 West Kendall Street, Cambridge, MA, United States, 02142 What is Alnylam Pharmaceuticals's ISIN number?
Alnylam Pharmaceuticals's international securities identification number is: US02043Q1076 What is Alnylam Pharmaceuticals's CUSIP number?
Alnylam Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 02043Q107
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert